The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | Video pages | Webcast | AKI to CKD transition

AKI to CKD transition

ERAKI & CKD-MBD Working Groups

Speaker
Yvelynne Kelly, Ireland

Panellists
Carlo Alfieri, Italy
Turgay Saritas, Germany

Moderator
Nick Selby, United Kingdom